#USA #Karyopharm #XPOVIO #Newton #KPTI

Karyopharm Therapeutics Grants Inducement Awards

On February 2, 2026, Karyopharm Therapeutics Inc., a company listed on the Nasdaq under the symbol KPTI, made a significant announcement regarding its approach to employee compensation. The commercial-stage pharmaceutical firm, known for its innovative cancer therapies, revealed that it had granted a total of 1,799 restricted stock units (RSUs) to four newly-hired employees.

Details of the Grants

These RSUs were awarded as part of the Company’s 2022 Inducement Stock Incentive Plan and took effect on January 31, 2026, coinciding with the individuals’ start dates. This move is in accordance with Nasdaq Listing Rule 5635(c)(4), which allows such incentives to attract key talent to the company.

Each award is structured to vest over a three-year period, meaning that one-third of the RSUs will become fully vested each year on the anniversary of the grant date, contingent upon the employee remaining with the company throughout that time.

This strategic decision highlights Karyopharm’s commitment to fostering a conducive environment for its employees, particularly in the competitive pharmaceutical industry. By offering these RSUs as incentives, the company aims to encourage employee retention and loyalty, which are crucial for driving long-term success in its mission against cancer.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. stands out in the oncology sector due to its dedication to innovative treatment solutions. The company has been a pioneer in developing oral compounds that focus on nuclear export dysregulation, a key factor in tumor development. Its leading product, XPOVIO® (selinexor), is an oral exportin 1 (XPO1) inhibitor that has gained approval in the United States across three different oncology indications.

Furthermore, Karyopharm’s reach extends beyond the U.S., with regulatory approvals in over 50 countries, including notable markets such as the European Union, the United Kingdom (where it’s known as NEXPOVIO®), and China. The company is dedicated to addressing high unmet needs in oncology, with a pipeline that targets multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).

Conclusion

Karyopharm’s latest grant of RSUs for new employees not only underscores its strategic talent acquisition strategy but also reflects its broader commitment to nurturing a workforce dedicated to transforming cancer treatment. The company's innovative approach, combined with an attractive incentive structure, positions Karyopharm well for continued growth and advances in the field of oncology. For further insights into their offerings and ongoing developments, Karyopharm encourages stakeholders to visit their official website and engage with them on LinkedIn and Twitter.

Follow Karyopharm on LinkedIn and Twitter for updates.